Miliotis, Christos
Ma, Yuling
Katopodi, Xanthi-Lida http://orcid.org/0000-0001-8555-777X
Karagkouni, Dimitra
Kanata, Eleni http://orcid.org/0009-0009-2828-2226
Mattioli, Kaia
Kalavros, Nikolas http://orcid.org/0000-0001-5503-9808
Pita-Juárez, Yered H. http://orcid.org/0000-0001-6992-252X
Batalini, Felipe http://orcid.org/0000-0003-3354-308X
Ramnarine, Varune R. http://orcid.org/0000-0002-6948-2744
Nanda, Shivani http://orcid.org/0000-0001-6358-2392
Slack, Frank J. http://orcid.org/0000-0001-8263-0409
Vlachos, Ioannis S. http://orcid.org/0000-0002-8849-808X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA232105, R01CA258776)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 16 October 2023
Accepted: 1 May 2024
First Online: 21 May 2024
Competing interests
: I.S.V. consults for Guidepoint Global, Cowen, Mosaic, and NextRNA. Beth Israel Deaconess Medical Center has filed a patent application based on this work for “Methods and compositions related to non-coding variants for the prediction of response to cancer immunotherapy” under 63/378,392, where I.S.V., F.J.S., C.M., and E.K. are named as co-inventors. The remaining authors declare no competing interests.